Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Palatin Technologies Inc

PTN ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$10.10

▲ +2.70%

Market Cap $17.96M · Vol 3.47K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$17.96M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

35.77

Momentum

Beta

N/A

vs Market

52W High

$30.50

66.90% below

52W Low

$7.25

39.24% above

Volume

3.47K

Avg 18.30K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

92.14%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Palatin Technologies Inc (PTN) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PTN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-7.04%

-1.13%

-1.51%

-51.93%

YTD

-34.36%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-17,307,350.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-247.09% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	1.78M

Technical Indicators

50-Day SMA	$9.80
200-Day SMA	$15.52
RSI (14)	35.77
Beta	N/A
52-Week High	$30.50
52-Week Low	$7.25

Volume Today	3.47K
Avg Daily Volume (30D)	18.30K
Relative Volume	0.19x
Volatility (10D)	151.28
Volatility (30D)	117.24
Free Float	92.14%

Analyst Consensus

BUY

Current Price $10.10

Mean Target $53.50

52W Low$7.25 52W High$30.50

Current

Target

$7.25 $30.50

Current Analyst target

+429.97% upside potential · 3 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001S8HM57

ISINUS6960776010

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateSep 21, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +2.24% ARGX.BR argenx SE +1.25% ARGX argenx SE -0.28% 2269.HK WuXi Biologics (Cayman) Inc. +2.12% INSM Insmed Incorporated -3.06%

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. The MCR system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. Its product development activities focus primarily on the use of MC4R agonists for treatment of obesity. It develops MC4R peptides and small molecule agonists with potential utility in obesity and metabolic-related disorders, rare MC4R pathway diseases, such as hypothalamic obesity, and orphan indications. It also develops MC1R agonist products to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease.